Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
The Supervisory Board of Fresenius Management SE extended Sara Hennicken's mandate as Chief Financial Officer (CFO) ahea…
MEMPHIS Electronic, the memory competence center with an unmatched portfolio of memory components and modules, is introd…
. - Fresenius achieves the raised outlook for FY/23. Strong final quarter with continued good development of the Operati…
Fresenius makes use of the governmental compensation and reimbursement payments of up to €300 million (from the curr…
Deconsolidation is a landmark in the implementation of the #FutureFresenius program and a historic day for both comp…
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, resol…
. - Excellent Group revenue growth of 6% in constant currency to €5.5 billion; driven by Operating Companies and Freseni…
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has a…
. • Powerful Cloud-Based Data Asset to Drive Improvements in Care Quality and Patient Outcomes as the Largest Multinatio…